About Ark Biosciences
Ark Biosciences is a Healthcare company based in Shanghai (China) founded in 2014. Chinese, clinical-stage biopharma developing small molecule therapeutics for respiratory viral infection and viral hepatitis. Its Indian entity Ark Biosciences Private Limited reported revenue of ₹9.91 Cr. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.
Company details
Ark Biosciences was founded in 2014 in Shanghai, China, as a clinical-stage biopharmaceutical company. Small molecule therapeutics targeting respiratory viral infections and viral hepatitis are developed by the firm. The lead candidate, AK0529, an oral inhibitor of RSV replication, has completed phase 1 trials and is advancing to phase 2. AK-612 for influenza remains in preclinical development, while two additional candidates address hepatitis B virus infections.
- Headquarters Shanghai, China
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website arkbiosciences.com
- Legal Name Ark Biosciences Private Limited
- Date of Incorporation 19 Jul, 2006
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹9.91 Cr
FY 2024 · -70% YoY
- Indian entity net profit₹1.55 Cr
FY 2024 · 16% margin
- Indian entity EBITDA₹2.27 Cr
FY 2024 · 23% margin
- InvestorsTPG
& 16 more
Associated legal entities of Ark Biosciences
Ark Biosciences operates through Ark Biosciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ark Biosciences Private Limited CIN U15495MH2006PTC163168 | Active | 19 Jul 2006 | Mumbai, Maharashtra | ₹9.9 Cr | 2 | View details |
Funding Insights of Ark Biosciences
- Total Rounds 3
- Investors Count 17
All 3 funding rounds of Ark Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | Series D | – | Loayal Valley Capital | ||
| Jan 2021 | Series C | – | Hillhouse, TPG | ||
| Apr 2015 | Series A | – | – |
17 investors in total: 17 institutional.
Investors in Ark Biosciences
Ark Biosciences has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Qiming Venture Partners and Visum Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mid-market companies are targeted for investment by Loayal Valley Capital. | loyalvalleycapital.com | Shanghai, China | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Private equity & venture capital firm | ftzfund.com.cn | Shanghai, China | ||
Multiple sectors are invested in by Oriental Fortune Capital. | ofcapital.com | Shenzhen, China | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
| yccapital.cn | ||||
Venture capital services are offered to support entrepreneurial growth. | dyeecapital.com | Xiamen, China | ||
| dtcap.com |
Investor details for Ark Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Ark Biosciences Private Limited (Ark Biosciences)
Ark Biosciences Private Limited is the primary company behind Ark Biosciences. The board of Ark Biosciences Private Limited currently have 2 directors; the longest-serving is Sharda Hariharan Iyer, appointed in 2006.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sharda Hariharan Iyer DIN 03274370 | Managing Director | 19 Jul 2006 | 20 yrs 3 mo | Ark Biosciences Private Limited |
| Hariharan Iyer Swaminathan DIN 05211598 | Director | 19 Jul 2006 | 20 yrs 3 mo | Ark Biosciences Private Limited |
Financials of Ark Biosciences
Figures of Ark Biosciences Private Limited, the primary company behind Ark Biosciences, for FY 2024. Revenue was ₹9.91 Cr (-70% year on year). Net profit was ₹1.55 Cr (16% margin). EBITDA was ₹2.27 Cr (23% margin). Revenue has grown at a compounded annual rate of -26% over three years and -1% over five years.
- ₹9.91 CrRevenue · FY 2024 · -70% YoY
- ₹1.55 CrNet profit · 16% margin
- ₹2.27 CrEBITDA · 23% margin
- ₹5 LakhPaid-up capital
- -26%Revenue CAGR, 3 years
- -1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ark Biosciences Private Limited are on its company page.
Detailed financial statements for Ark Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ark Biosciences
3 dated milestones of Ark Biosciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ark Biosciences is founded.
- Funding First funding round.
- Funding Latest funding round, Series D,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ark Biosciences
Complete news archive for Ark Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ark Biosciences
Ark Biosciences was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Ark Biosciences is headquartered in Shanghai, China.
The primary company behind Ark Biosciences, Ark Biosciences Private Limited, reported revenue of ₹9.91 Cr for FY 2024, down 70% year on year.
Ark Biosciences was founded in 2014 in Shanghai, China, as a clinical-stage biopharmaceutical company. Small molecule therapeutics targeting respiratory viral infections and viral hepatitis are developed by the firm. The lead candidate, AK0529, an oral inhibitor of RSV replication, has completed phase 1 trials and is advancing to phase 2. AK-612 for influenza remains in preclinical development, while two additional candidates address hepatitis B virus infections.
Ark Biosciences has 17 investors. Key investors include TPG, Qiming Venture Partners, Visum Pharma, Loayal Valley Capital, and Longda Food Group.
Ark Biosciences operates through Ark Biosciences Private Limited.
The legal entities of Ark Biosciences currently have 2 directors, including Sharda Hariharan Iyer, Hariharan Iyer Swaminathan.